{"title":"Probiotics and Herbals as a Boom in Treatment of Ulcerative Colitis","authors":"Sankha Bhattacharya","doi":"10.22377/ajp.v14i2.3627","DOIUrl":null,"url":null,"abstract":"Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are variable. In its most limited form, it may be restricted to the distal rectum, while in its most extended form, the entire colon is involved. UC is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and immunosuppressant are used for therapy of UC. The annual occurrence of disease in Asia, America, and Europe was estimated to be 6.3, 19.2, and 24.3/100,000 people years. The main challenges in the management of the disease are drug-related side effects and local targeting. To overcome these challenges, probiotics overcome drug-related adverse side effects and local targeting. On ingestion, the probiotics can result in health beneficial effects. Probiotics are mainly used as gut modulators but are also nowadays explored for their use in UC.","PeriodicalId":8489,"journal":{"name":"Asian Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2020-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22377/ajp.v14i2.3627","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 4
Abstract
Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are variable. In its most limited form, it may be restricted to the distal rectum, while in its most extended form, the entire colon is involved. UC is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and immunosuppressant are used for therapy of UC. The annual occurrence of disease in Asia, America, and Europe was estimated to be 6.3, 19.2, and 24.3/100,000 people years. The main challenges in the management of the disease are drug-related side effects and local targeting. To overcome these challenges, probiotics overcome drug-related adverse side effects and local targeting. On ingestion, the probiotics can result in health beneficial effects. Probiotics are mainly used as gut modulators but are also nowadays explored for their use in UC.
期刊介绍:
Character of the publications: -Pharmaceutics and Pharmaceutical Technology -Formulation Design and Development -Drug Discovery and Development Interface -Manufacturing Science and Engineering -Pharmacokinetics, Pharmacodynamics, and Drug Metabolism -Clinical Pharmacology, General Medicine and Translational Research -Physical Pharmacy and Biopharmaceutics -Novel Drug delivery system -Biotechnology & Microbiological evaluations -Regulatory Sciences